Sons born to mothers with high serum levels of polychlorinated biphenyls (PCBs) or polybrominated biphenyls (PBBs) are significantly more likely to have congenital urologic anomalies, according to research recently presented at the Annual Scientific Meeting of the American Urological Association in Orlando, FL.
Sons born to mothers with high serum levels of polychlorinated biphenyls (PCBs) or polybrominated biphenyls (PBBs) are significantly more likely to have congenital urologic anomalies, according to research recently presented at the Annual Scientific Meeting of the American Urological Association in Orlando, FL.
In one study, John J. Chen, PhD, of the Stony Brook University Medical Center in Stony Brook, NY, and colleagues analyzed serum levels of PCBs in 27 infant boys who underwent surgery for cryptorchidism and 13 controls. They also analyzed levels in all of the subjects' mothers. The investigators found that maternal levels of individual PCB congeners as well as aggregate PCBs were significantly higher in mothers of boys with cryptorchidism than in mothers of controls and correlated well with the sons' serum levels.
In a second study, John J. DeCaro, MD, of the Emory University School of Medicine in Atlanta, and colleagues analyzed data on individuals accidentally exposed to PBBs during 1973-1974 and studied male offspring born to women with a known serum PBB level. They found that sons with an estimated maternal PBB concentration of more than 5 parts per billion at conception were nearly four times as likely to report varicocele, cryptorchidism, hypospadias, and related conditions, compared with sons with an estimated maternal PBB concentration of less than 1 part per billion (OR, 3.53).
"Mothers with known exposure to these enduring compounds should tell not only their own doctors but also their sons' pediatricians," Anthony Y. Smith, MD, a spokesman for the AUA, said in a statement. "These data underscore the importance of regular 'well-baby checkups' so that these easily treatable conditions are diagnosed promptly."
More information is available at http://www.aua2008.org/ (see abstracts 276, 277).
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More